Thursday, July 9, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Jul 8, 2026
FDA halts release of new drug rejection letters while working to formalize policy
background ▾
- •The FDA's real-time CRL publication policy has been paused since April 2024 amid legal challenge regarding protection of proprietary information and inadequate redactions in previously published letters.
- •The unnamed petitioning company, represented by Covington & Burling, documented specific instances of unredacted confidential material in CRLs from companies including Lykos Therapeutics and Stealth BioTherapeutics.
- •The FDA continues pursuing formalization of CRL transparency through proposed rulemaking and congressional amendments, indicating the policy pause is procedural rather than abandonment—watch for regulatory text and legislative movement as leadership transitions occur.
AbbVieSobiUltragenyxtrenibotulinumtoxinERP1 (vusolimogene oderparepvec)
→ Read original articlePolicy•STAT News•Jul 9, 2026
What happens on ‘MAHA Monday’?
background ▾
- •The MAHA movement is conducting public outreach on health and wellness priorities through grassroots events, signaling potential future policy direction
Policy•STAT News•Jul 9, 2026
Opinion: Who benefits from classifying obesity as a disease?
background ▾
- •Disease classification of obesity creates a direct commercial advantage for anti-obesity drug developers by legitimizing long-term pharmaceutical treatment and enabling insurance reimbursement and expedited drug approvals.
- •The AMA's 2013 decision to classify obesity as a disease, despite its own council finding insufficient evidence, exemplifies how disease designation is a political and institutional process rather than purely scientific adjudication.
- •Watch how payer reimbursement policies, regulatory pathways, and public health spending shift as obesity's disease status becomes institutionalized—and whether outcomes data eventually validate the medical vs. public health intervention trade-off.
Eli LillyNovo Nordisk
→ Read original articlePolicy•STAT News•Jul 9, 2026
Opinion: Your grandparents are using cannabis. Doctors can help them do it safely
background ▾
- •Senior patients represent a significant and rapidly growing segment of medical cannabis users, but face unique safety risks due to age-related pharmacokinetic changes and modern product potency levels 10-fold higher than historical cannabis
- •Large multistate cannabis operators are increasingly prioritizing high-THC formulations for profit maximization rather than therapeutic balance, a practice the author compares unfavorably to tobacco and alcohol industry strategies
cannabisTHCCBD
→ Read original articlePolicy•Fierce Biotech•Jul 8, 2026
Prime wins patent fight with Beam to continue work on AATD gene editing therapy
background ▾
- •Arbitration tribunal ruled Prime did not breach its 2019 agreement with Beam and owes no damages, allowing PM647 to advance clinically for AATD
- •Both companies use similar CRISPR-based approaches (base editing vs. prime editing) targeting the same SERPINA1 PiZ mutation, but Beam maintains it retains exclusive rights to transition edits in AATD
- •Watch for continued IP litigation between these parties and Prime's other disputes with CRISPR Therapeutics and Tessera, which may reshape competitive positioning in prime/base editing space
Prime MedicineBeam TherapeuticsCRISPR TherapeuticsPM647BEAM-302
→ Read original articleMarket Access
Market Access•Fierce Biotech•Jul 8, 2026
Scipher picks up Chemomab’s liver disease drug, Nasdaq listing in all-stock merger
background ▾
- •Nebokitug represents the first precision medicine approach to RA with a novel mechanism (anti-CCL24) in over a decade, targeting patients inadequately treated by current therapies.
- •The merged company combines a clinical-stage asset (nebokitug) with revenue-generating precision diagnostics, creating a hybrid business model with dual value drivers.
- •Combined entity valued at $150 million pre-placement with potential to de-risk RA development through biomarker-driven patient selection and maintain parallel PSC opportunity with potential pharma partnership for phase 3.
Scipher MedicineChemomab Therapeuticsnebokitug
→ Read original articleMarket Access•KFF•Jul 8, 2026
Contraceptive Implants: Access and Coverage in the U.S.
background ▾
- •Nexplanon remains the sole contraceptive implant available in the U.S. market, with a 0.05% failure rate making it the most effective reversible contraceptive option, yet adoption is limited by access and awareness barriers rather than efficacy concerns
- •High upfront inventory costs and provider training requirements create structural barriers to market penetration despite strong clinical evidence and endorsement by major medical societies (ACOG, AAP)
MerckOrganon USANexplanonetonogestrel
→ Read original articleMarket Access•Fierce Biotech•Jul 8, 2026
Leo Cancer Care secures $65M to advance upright radiotherapy system as company preps for IPO
background ▾
- •Leo Cancer Care's upright radiotherapy platform reduces proton therapy system costs by approximately 50% compared to conventional systems exceeding $100 million, directly addressing a critical market access barrier in global cancer care.
- •The company is preparing for a high-valuation IPO at year-end 2024 backed by $155 million in cumulative funding, signaling strong investor confidence in the radiotherapy innovation space and potential for transformative reimbursement/pricing strategies.
- •Monitor the unnamed strategic healthcare partner announcement and IPO timing, as these will determine market penetration velocity and whether cost reduction translates to actual expanded patient access in underserved regions.
Leo Cancer CareYu GalaxyEventide Asset Management
→ Read original articleMarket Access•Fierce Biotech•Jul 7, 2026
Caidya and Simbec-Orion unite in global CRO combo
background ▾
- •Caidya (backed by $165M from Rubicon Founders) absorbs Simbec-Orion's 50-year European early-phase platform, expanding both companies' geographic and service reach across FIH-to-registration development.
- •The merger enhances Simbec-Orion's access to U.S. and Asia-Pacific markets while strengthening Caidya's phase 1 and European operations—a straightforward operational consolidation with no disclosed material changes to pricing, capacity, or scientific capabilities.
CaidyaSimbec-OrionRubicon Founders
→ Read original articleMarket Access•Endpoints News•Jul 8, 2026
Biohaven looks to take on Lilly in the muscle-sparing obesity space
background ▾
- •Biohaven is entering/expanding in the muscle-sparing obesity market to challenge Eli Lilly's dominance in this emerging segment
- •The obesity drug market is attracting multiple competitors seeking differentiation through muscle-sparing mechanisms
Biohaven PharmaceuticalsEli Lilly
→ Read original articleClinical Trials
Clinical Trials•Endpoints News•Jul 9, 2026
AstraZeneca sinks on unexpected heart drug trial failure
background ▾
- •Late-stage trial failure for a major pharma-biotech collaboration eliminates a potential cardiovascular asset and demonstrates pipeline risk
- •Market immediately repriced AstraZeneca equity downward, indicating substantial commercial expectations had been assigned to this program
- •Unclear whether AstraZeneca will attempt dose optimization, patient population enrichment, or pursue alternative indications before making a final development decision
AstraZenecaIonis Pharmaceuticals
→ Read original articleClinical Trials•Fierce Biotech•Jul 8, 2026
Satellos’ ‘intriguing’ Duchenne data raise hopes ahead of key readout
background ▾
- •SAT-3247 demonstrated consistent improvements in muscle fat fraction (primary endpoint) and multiple secondary endpoints in all four adult DMD patients at six months—notably achieving reduction (not just slowing) of fat deposition, a claimed first among DMD therapies.
- •Basecamp pediatric trial (ages 7-10) enrollment expected to complete Q3 2024 with topline data due Q4 2024; this readout will determine whether adult efficacy translates to children and validate the commercial opportunity.
- •Watch Q4 2024 for Basecamp topline results and one-year adult data; any failure to replicate efficacy in children or worsening safety profile would substantially diminish commercial potential.
Satellos BioscienceSAT-3247
→ Read original article